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Abstract: This study is aimed at evaluating the potential of a biochip assay to sensitively 
detect KRAS mutation in DNA from non-small cell lung cancer (NSCLC) tissue samples. 
The assay covers 10 mutations in codons 12 and 13 of the KRAS gene, and is based on 
mutant-enriched PCR followed by reverse-hybridization of biotinylated amplification 
products to an array of sequence-specific probes immobilized on the tip of a rectangular 
plastic stick (biochip). Biochip hybridization identified 17 (21%) samples to carry a KRAS 
mutation of which 16 (33%) were adenocarcinomas and 1 (3%) was a squamous cell 
carcinoma. All mutations were confirmed by DNA sequencing. Using 10 ng of starting 
DNA, the biochip assay demonstrated a detection limit of 1% mutant sequence in   
a background of wild-type DNA. Our results suggest that the biochip assay is a   
sensitive alternative to protocols currently in use for KRAS mutation testing on limited 
quantity samples. 
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1. Introduction 
Lung cancer is one of the most common human cancers and is the leading cause of cancer death 
worldwide, with non-small cell lung cancer (NSCLC) accounting for up to 85% of all cases [1]. In 
lung carcinoma, epidermal growth factor receptor (EGFR) is more abundantly expressed than in 
adjacent normal lung [2]. EGFR signaling pathways include downstream GTPases encoded by RAS 
genes, and the incidence of activating KRAS mutation in patients with NSCLC ranges from 8% to 24% 
with most mutations located in codons 12 and 13 at exon 2 [3,4]. Interestingly, KRAS mutations are 
frequently found in histologically normal tissues near tumors, suggesting that such mutations may 
represent an early event in lung carcinogenesis [5]. Somatic gain-of-function mutations in the tyrosine 
kinase domain of the EGFR have been identified in up to 40% of NSCLC patients [6], and these 
mutations are associated with sensitivity to small-molecule tyrosine kinase inhibitors like gefitinib or 
erlotinib [7]. EGFR and KRAS mutations have been reported to be mutually exclusive, and NSCLC 
patients carrying a KRAS mutation do not respond to tyrosine kinase inhibitors [8]. Additionally, KRAS 
mutation seem to be associated with unfavorable outcomes making KRAS both a predictive and a 
prognostic marker in NSCLC [3], although its predictive role is still inconclusive as indicated by 
several recent studies [4]. 
Recently, a low-density biochip assay, designed for the sensitive detection of 10 mutations in 
codons 12 and 13 of the KRAS gene (Val12, Asp12, Leu12, Ser12, Ala12, Ile12, Cys12, Arg12, Cys13, 
Asp13) has successfully been introduced to KRAS mutation screening in ovarian cancer [9–11]. The 
assay is based on peptide nucleic acid (PNA)-mediated mutant-enriched PCR and reverse-hybridization 
of amplification products to oligonucleotide probes immobilized on the tip of a rectangular plastic 
stick (biochip) [9]. The biochip assay demonstrated an analytical sensitivity of 0.1% using dilutions of 
genomic DNA prepared from tumor cell lines [9], whereas a loss of sensitivity was observed when the 
assay was performed on formalin-fixed paraffin-embedded (FFPE)-extracted DNA [11]. 
This study is aimed at evaluating the potential of the biochip assay to sensitively detect mutant 
KRAS in 81 NSCLC samples, and the presence of KRAS mutation was then verified by DNA sequencing. 
2. Results and Discussion 
The biochip assay’s limit for detecting KRAS mutations was exemplified using 0.1 ng of tumor cell 
line DNA mixed with 10 ng of wild-type DNA. Suppression of wild-type amplification by PNA 
clamping using 10 ng of wild-type template was found to be complete (Figure 1A), whereas KRAS 
mutation Cys12 contained in cell line MIA Paca2 was unambiguously identified, demonstrating an 
analytical sensitivity of 1% for the biochip assay (Figure 1C). Suppression of wild-type amplification 
using 100 ng of wild-type template was incomplete as indicated by the KRAS control spots (Figure 1B). 
The presence of KRAS wild-type PCR product, however, did not result in signals derived from   
KRAS-specific capture probes ensuring high specificity of the biochip assay.  Int. J. Mol. Sci. 2011, 12               
 
8532
Figure 1. Chemiluminescent images after biochip hybridization are shown. Mutant-enriched 
PCR was performed using either 10 ng (A) or 100 ng (B) wild-type DNA (Colo320), and a 
mixture of 0.1 ng mutant (MIA Paca2) and 10 ng wild-type DNA (Colo320) (C). Control 
spots (Ctrl) were included to monitor for DNA extraction, suppression of KRAS wild-type 
amplification (KRAS control), and hybridization stringency. 
 
Genomic DNA was isolated and amplified by mutant-enriched PCR from 81 primary NSCLC 
tumors including 48 adenocarcinomas, 30 squamous cell carcinomas and 3 large cell carcinomas. 
Biochip-based analysis of resulting PCR products identified 17 (21%) of 81 samples to carry a KRAS 
mutation of which 16/48 (33%) were adenocarcinomas and 1/30 (3%) was a squamous cell carcinoma 
(Table 1). 
No mutation was detected in the 3 large cell carcinomas. Mutations were exclusively located in 
codon 12, with Asp12 (35%) being most frequent, followed by Cys12 (29%) and Val12 (18%) (Table 2). 
All mutations were confirmed by direct sequencing (data not shown).  
With respect to disease stage, KRAS mutations were found in 33% (8/24) of patients with stage I, in 
13% (2/15) of patients with stage IB, in 36% (4/11) of patients with stage IIA, and in 20% (3/15) of 
patients with stage IIIA (Table 1). No mutations were detected in patients with stages IIB and IIIB. Int. J. Mol. Sci. 2011, 12               
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Table 1. Characteristics of 81 non-small cell lung cancer (NSCLC) specimens. 
Characteristic  n  Mutated, n (%) 
Total 81  17  (21) 
Gender 
Male 59  11  (19) 
Female 22  6  (27) 
Pathology 
Squamous cell carcinoma  30  1 (3) 
Adenocarcinoma 48 16  (33) 
Large cell carcinoma  3  0 (0) 
Differentiation 
Grade 1  3  0 (0) 
Grade 2  53  12 (23) 
Grade 3  20  3 (15) 
Unknown 5  2  (40) 
Disease stage 
IA 24  8  (33) 
IB 15  2  (13) 
IIA 11  4  (36) 
IIB 14  0  (0) 
IIIA 15  3  (20) 
IIIB 2  0  (0) 
Pathologic tumor status 
pT1 32  11  (34) 
pT2 40  5  (12) 
pT3 7  1  (14) 
pT4 2  0  (0) 
Pathologic lymph node status 
pN0 45  10  (22) 
pN1 22  5  (23) 
pN2 14  2  (14) 
Table 2. Identity of 17 KRAS mutations detected by biochip hybridization. 
Mutation Amino  acid n  % 
GGT→GAT Gly12→Asp12 6  35 
GGT→TGT Gly12→Cys12 5  29 
GGT→GTT Gly12→Val12 3  18 
GGT→GCT Gly12→Ala12 2  12 
GGT→AGT Gly12→Ser12 1  6 
GGT→CGT Gly12→Arg12 0  0 
GGT→ATT Gly12→Ile12 0  0 
GGT→CTT Gly12→Leu12 0  0 
GGC→GAC Gly13→Asp13 0  0 
GGC→TGC Gly13→Cys13 0  0 
 Total  17  100 
To determine the assay’s mutation detection limit in clinical specimens, mutant-enriched PCR was 
performed on genomic DNA isolated from 17 mutant NSCLC samples diluted 1:10 and 1:100 with 
wild-type DNA. Subsequent biochip hybridization was able to detect KRAS mutation present in all 
dilutions (data not shown), thereby supporting an analytical sensitivity of 1% for the biochip assay.  Int. J. Mol. Sci. 2011, 12               
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In this work, we analyzed 81 NSCLC tissue samples using a biochip assay designed for the 
sensitive detection of 10 mutations in codons 12 and 13 of the KRAS gene. Seventeen (21%) tumor 
samples contained a KRAS mutation, all of which were located in codon 12. This finding is in line with 
other studies that observed KRAS mutations among 20–33% of NSCLC patients with the majority of 
mutations being guanine to thymine transversions in codon 12 [12,13]. With respect to histotype,  
16 (33%) of 48 adenocarcinomas and 1 (3%) of 30 squamous cell carcinomas were positive for a 
KRAS mutation. The increased prevalence of KRAS mutations in adenocarcinoma observed here 
corroborates earlier findings [12].  
Using 10 ng of starting DNA, the biochip assay demonstrated a detection limit of 1% mutant 
sequence in a background of normal DNA. Therefore, this assay seems suitable for the detection of 
KRAS mutation in lung cancer because biopsies and FFPE sections are often small in size, thereby 
limiting template availability [13]. Similarly, low amount of cellular material is usually obtained by 
minimally invasive techniques such as transbronchial or transesophageal aspiration of the mediastinal 
lymph nodes [14].  
More recent work used this biochip assay to screen for KRAS mutations in 85 DNA samples 
isolated from ovarian tissue [9]. In that study, all mutations detected by biochip hybridization were 
confirmed by sequencing after mutant-enriched PCR, thus being concordant with the results presented 
in this report. Subsequent studies including a total of 523 ovarian tissue samples indicate, that the 
biochip assay is fully compatible with KRAS mutation analysis in genomic DNA isolated from FFPE  
material [10,11]. This is of importance, because FFPE specimens are most commonly used for the 
detection of KRAS mutation.  
Various molecular diagnostic methodologies such as DNA sequencing, capillary electrophoresis, 
amplification refractory mutation system (ARMS), and high resolution melting analysis (HRM) are 
available for KRAS mutation analysis [15–19]. All these methods have their advantages and 
disadvantages in terms of operational input, sample throughput, cost, and sensitivity. 
Although labor-intensive and not very sensitive (i.e., analytical sensitivity of 20%), direct sequencing 
remains the gold standard for the detection of KRAS mutation in routine diagnostics [16,19]. A 
quantitative and more sensitive sequencing by synthesis approach (pyrosequencing) has been 
described demonstrating an analytical sensitivity of 5% on mixed DNA samples containing various 
amounts of mutant template [18]. In-tube real-time diagnostic procedures such as ARMS and HRM are 
rapid and sensitive to detect 1% and 5% to 6% mutant KRAS in a background of normal DNA, 
respectively [15,17], however, multiplexing possibilities are limited. Recently, a semiquantitative 
assay based on single nucleotide primer extension (SNaPshot) followed by capillary electrophoresis 
was shown to be a flexible alternative to direct sequencing for KRAS mutation analysis in colorectal 
FFPE DNA samples [16]. While being similar with respect to workflow, time to results, hands-on time, 
and costs, the SNaPshot assay is more sensitive, demonstrating a detection limit of 10% tumor cells. 
Moreover, SNaPshot offers a flexible assay design which might be easily modified to contain 
additional mutations. 
Using 10 ng of starting DNA, the biochip assay described here allows simultaneous detection of  
10 frequent KRAS mutations with a sensitivity of 1% mutant sequence in a background of wild-type 
DNA. The procedure is relatively fast (<6 h excluding DNA isolation), however, biochip hybridization 
is labor-consuming and data collection by chemiluminescence imaging lacks parallel processing ability, Int. J. Mol. Sci. 2011, 12               
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thereby limiting daily throughput to ≤24 samples. To evaluate the impact of DNA quality on template 
input and assay sensitivity, biochip analyses of DNA extracted from FFPE tissues are currently in 
progress. 
3. Experimental Section 
3.1. Tissue Samples and DNA Isolation 
Primary NSCLC tumors (n = 81) were obtained from patients who had received surgical resections. 
There were 59 male and 22 female NSCLC patients, ages 42–82 years (mean, 64 years) at diagnosis. 
24 patients had stage IA disease, 15 patients had stage IB disease, 11 patients had stage IIA disease,  
14 patients had stage IIB disease, 15 patients had stage IIIA disease and 2 patients had stage IIIB 
disease. Histological subtypes of primary NSCLCs included 48 adenocarcinomas, 30 squamous cell 
carcinomas and 3 large cell carcinomas. Genomic DNA was isolated from frozen lung tumors by 
digestion with Proteinase K, followed by standard phenol-chloroform extraction and ethanol 
precipitation [20]. 
Patients gave their written informed consent and the study was approved by the local institutional 
review boards.  
3.2. Mutant-Enriched PCR and Biochip Hybridization 
Mutant-enriched duplex PCR and reverse-hybridization of PCR products to biochips was done as 
described earlier except for the fact that PCR was run for extra 10 cycles (i.e., 45 cycles) [11]. Briefly, 
downstream primers were biotinylated and upstream primers were phosphorylated at the 5′-position. 
PCR was performed in a 25 μL reaction, containing 1× PCR Buffer (Qiagen, Hilden, Germany),   
100 μM each deoxyribonucleoside triphosphate, 0.1 μM HLA-DRA primers, 0.25 μM KRAS primers, 
2.84 μM PNA, 1 U Hot Star Taq Polymerase (Qiagen) and 10 ng DNA template. Amplifications were 
performed on a PE9700 cycler (Applied Biosystems, Foster City, CA) starting with an initial 
denaturation step at 95 °C for 15 min, then running for 45 cycles as follows: 94 °C for 1 min, 70 °C for 
50 s, 58 °C for 50 s, 72 °C for 50 s, and a final extension at 72 °C for 7 min. 
For biochip hybridization, 20 µL of PCR product was digested with 1 µL lambda exonuclease  
(New England BioLabs Inc., Ipswich, MA) at RT for 30 min. 10 µL of digested PCR product was then 
diluted in 200 µL of a solution containing 6× saline-sodium phosphate-EDTA (Sigma-Aldrich,   
St. Louis, MO) and 1 mL/L Tween 20 (Sigma) including a hybridization control target. Hybridization 
of the biochip was performed at 37 °C for 1 h in a conventional thermoshaker (Eppendorf AG, 
Hamburg, Germany). Without additional washing steps, the biochip was incubated for 15 min with 
streptavidin-peroxidase conjugate (Sigma) and thereafter rinsed with 1 mL 6× saline-sodium 
phosphate-EDTA (Sigma) containing 1 mL/L Tween 20 (Sigma). Upon addition of substrate 
(Chemiluminescent Peroxidase Substrate-3; Sigma), biochip signals were measured with a 
chemiluminescence detector developed for use with the biochip [9]. Images were displayed with the 
ImagQuant version 5.0 software (Molecular Dynamics), and genotyping calls were then made 
according to a set of quality criteria determined previously [21]. Int. J. Mol. Sci. 2011, 12               
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Genomic DNA isolated from tumor cell lines MIA Paca2 (Cys12) and Colo320 (wild-type) served 
as control templates and were included in each independent experimental set-up. 0.1 ng mutant 
genomic DNA mixed with 10 ng wild-type DNA and 10 or 100 ng wild-type DNA alone were used to 
monitor assay sensitivity and specificity, respectively. To determine the biochip assay’s limit for 
detecting KRAS mutation in NSCLC samples, PCR was performed on mutant DNA diluted 1:10 and 
1:100 with wild-type DNA.  
3.3. Dideoxy Sequencing 
For DNA sequencing, KRAS-positive PCR products were column purified using the GenElute PCR 
CleanUp Kit (Sigma), and sequence analysis was performed on a ABI 310 automatic sequencer 
(Applied Biosystems) according to the manufacturer’s instructions (BigDye Terminator v1.1 Cycle 
Sequencing Kit; Applied Biosystems) using the KRAS sense primer. 
4. Conclusions 
Tailored therapy approaches have prompted the need for predictive biomarkers as drugs are costly 
and patients could be spared the side effects of pointless treatment. Recent data demonstrated that in 
NSCLC, the predictive role of KRAS is still inconclusive, and further studies should rely on methods 
optimized for the sensitive detection of KRAS mutation because biopsies and FFPE sections are often 
small in size, thereby limiting template availability. Using 10 ng of starting DNA, the biochip assay 
described here allows simultaneous detection of 10 frequent KRAS mutations with a sensitivity of 1% 
mutant sequence in a background of wild-type DNA, thereby making it a sensitive alternative to 
protocols currently in use for KRAS mutation testing on limited quantity samples. 
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